Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.830
-0.100 (-3.41%)
At close: May 5, 2026, 4:00 PM EDT
2.900
+0.070 (2.47%)
After-hours: May 5, 2026, 7:47 PM EDT
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$315,304
Profits / Employee
-$745,304
Market Cap
489.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 23 | 0 | - |
| Dec 31, 2024 | 23 | -17 | -42.50% |
| Sep 30, 2024 | 25 | -14 | -35.90% |
| Jun 30, 2024 | 40 | 0 | - |
| Mar 31, 2024 | 40 | -6 | -13.04% |
| Dec 31, 2023 | 40 | -4 | -9.09% |
| Sep 30, 2023 | 39 | -5 | -11.36% |
| Jun 30, 2023 | 40 | -4 | -9.09% |
| Mar 31, 2023 | 46 | -3 | -6.12% |
| Dec 31, 2022 | 44 | -13 | -22.81% |
| Sep 30, 2022 | 44 | -1 | -2.22% |
| Jun 30, 2022 | 44 | -16 | -26.67% |
| Mar 31, 2022 | 49 | -15 | -23.44% |
| Dec 31, 2021 | 57 | -10 | -14.93% |
| Sep 30, 2021 | 45 | -20 | -30.77% |
| Jun 30, 2021 | 60 | 0 | - |
| Mar 31, 2021 | 64 | -1 | -1.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 300 |
| ADC Therapeutics | 193 |
| enGene Therapeutics | 82 |
| Prelude Therapeutics | 79 |
| Fulcrum Therapeutics | 55 |
| Candel Therapeutics | 55 |
| Contineum Therapeutics | 51 |
| Eupraxia Pharmaceuticals | 49 |
OVID News
- 21 days ago - Ovid Therapeutics Transcript: Status update - Transcripts
- 27 days ago - Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - GlobeNewsWire
- 6 weeks ago - Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Benzinga
- 6 weeks ago - Ovid Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Ovid Therapeutics Announces Pricing of $60 Million Private Placement - GlobeNewsWire
- 7 weeks ago - Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts